Nektar to Webcast Presentation of Phase 1 Clinical Results for LeadSmall Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
SAN CARLOS, Calif., May 30, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinotecan). The Webcast will include a presentation by featured speaker Dr. Daniel D. Von Hoff, M.D., F.A.C.P, the lead investigator for the NKTR-102 Phase 1 trial. Dr. Von Hoff is Physician-in-Chief and Senior Investigator at the Translational Genomics Research Institute (TGen), Chief Scientific Officer for the Scottsdale Clinical Research Institute at Scottsdale Healthcare, and Chief Scientific Officer of US Oncology.
Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation technology has enabled eight approved products for partners, which include leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.
Contact: Jennifer Ruddock, +1-650-283-6253, firstname.lastname@example.org
CONTACT: Jennifer Ruddock of Nektar Therapeutics, +1-650-283-6253, email@example.com
Web site: http://www.nektar.com/
Ticker Symbol: (NASDAQ-NMS:NKTR)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: May 2008